Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

234 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors.
Lockhart AC, Howard M, Hande KR, Roth BJ, Berlin JD, Vreeland F, Campbell A, Fontana E, Fiorentini F, Fowst C, Paty VA, Lankford O, Rothenberg ML. Lockhart AC, et al. Among authors: berlin jd. Clin Cancer Res. 2004 Jan 15;10(2):468-75. doi: 10.1158/1078-0432.ccr-0658-03. Clin Cancer Res. 2004. PMID: 14760067 Clinical Trial.
Phase I, pharmacokinetic and biological correlative study of OSI-7904L, a novel liposomal thymidylate synthase inhibitor, and cisplatin in patients with solid tumors.
Ricart AD, Berlin JD, Papadopoulos KP, Syed S, Drolet DW, Quaratino-Baker C, Horan J, Chick J, Vermeulen W, Tolcher AW, Rowinsky EK, Rothenberg ML. Ricart AD, et al. Among authors: berlin jd. Clin Cancer Res. 2008 Dec 1;14(23):7947-55. doi: 10.1158/1078-0432.CCR-08-0864. Clin Cancer Res. 2008. PMID: 19047127 Clinical Trial.
Phase I pharmacokinetic and pharmacodynamic study of SJG-136, a novel DNA sequence selective minor groove cross-linking agent, in advanced solid tumors.
Puzanov I, Lee W, Chen AP, Calcutt MW, Hachey DL, Vermeulen WL, Spanswick VJ, Liao CY, Hartley JA, Berlin JD, Rothenberg ML. Puzanov I, et al. Among authors: berlin jd. Clin Cancer Res. 2011 Jun 1;17(11):3794-802. doi: 10.1158/1078-0432.CCR-10-2056. Epub 2011 Feb 23. Clin Cancer Res. 2011. PMID: 21346148 Free PMC article. Clinical Trial.
A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer.
Berlin J, Bendell JC, Hart LL, Firdaus I, Gore I, Hermann RC, Mulcahy MF, Zalupski MM, Mackey HM, Yauch RL, Graham RA, Bray GL, Low JA. Berlin J, et al. Clin Cancer Res. 2013 Jan 1;19(1):258-67. doi: 10.1158/1078-0432.CCR-12-1800. Epub 2012 Oct 18. Clin Cancer Res. 2013. PMID: 23082002 Clinical Trial.
Aflibercept.
Ciombor KK, Berlin J, Chan E. Ciombor KK, et al. Clin Cancer Res. 2013 Apr 15;19(8):1920-5. doi: 10.1158/1078-0432.CCR-12-2911. Epub 2013 Feb 26. Clin Cancer Res. 2013. PMID: 23444216 Free PMC article.
Phase II trial of sorafenib and erlotinib in advanced pancreatic cancer.
Cardin DB, Goff L, Li CI, Shyr Y, Winkler C, DeVore R, Schlabach L, Holloway M, McClanahan P, Meyer K, Grigorieva J, Berlin J, Chan E. Cardin DB, et al. Cancer Med. 2014 Jun;3(3):572-9. doi: 10.1002/cam4.208. Epub 2014 Feb 12. Cancer Med. 2014. PMID: 24574334 Free PMC article. Clinical Trial.
234 results